Amylyx Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase (Decrease) in Accounts Receivable of -$359.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-03-03
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$44.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $30.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was -$198.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was -$147.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$359.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$39.60M, a 260.05% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $24.74M, a 61.66% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $15.31M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$14.00K derived: sum of 2 quarters · filed 2026-03-03 | -$212.00K derived: sum of 3 quarters · filed 2026-03-03 | -$359.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$168.00K derived: sum of 2 quarters · filed 2025-11-06 | -$315.00K 10-Q · filed 2025-11-06 | -$1.60M derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | -$198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$345.00K 10-Q · filed 2025-08-07 | -$1.63M derived: sum of 3 quarters · filed 2026-03-03 | -$3.99M derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | -$147.00K 10-Q · filed 2025-05-08 | -$1.43M derived: sum of 2 quarters · filed 2026-03-03 | -$3.79M derived: sum of 3 quarters · filed 2026-03-03 | -$20.05M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$3.64M derived: sum of 2 quarters · filed 2026-03-03 | -$19.90M derived: sum of 3 quarters · filed 2026-03-03 | -$39.60M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$18.62M derived: sum of 2 quarters · filed 2025-11-06 | -$38.32M 10-Q · filed 2025-11-06 | -$27.62M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$16.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$35.96M 10-Q · filed 2025-08-07 | -$25.26M derived: sum of 3 quarters · filed 2025-08-07 | -$29.38M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$19.70M 10-Q · filed 2025-05-08 | -$9.00M derived: sum of 2 quarters · filed 2025-05-08 | -$13.12M derived: sum of 3 quarters · filed 2025-05-08 | $2.80M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $6.58M derived: sum of 2 quarters · filed 2025-03-04 | $22.50M derived: sum of 3 quarters · filed 2025-03-04 | $24.74M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $11.80M derived: sum of 2 quarters · filed 2024-11-07 | $14.05M 10-Q · filed 2024-11-07 | $29.22M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $15.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $18.17M 10-Q · filed 2024-08-08 | $33.34M derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $2.25M 10-Q · filed 2024-05-09 | $17.42M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $15.31M 10-K · filed 2024-02-22 | ||
| 2022-09-30 | $137.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |